These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 22286314)

  • 1. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
    Kuter I; Gee JM; Hegg R; Singer CF; Badwe RA; Lowe ES; Emeribe UA; Anderson E; Sapunar F; Finlay P; Nicholson RI; Bines J; Harbeck N
    Breast Cancer Res Treat; 2012 May; 133(1):237-46. PubMed ID: 22286314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer.
    Young OE; Renshaw L; Macaskill EJ; White S; Faratian D; Thomas JS; Dixon JM
    Eur J Cancer; 2008 Feb; 44(3):391-9. PubMed ID: 18083023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer.
    Robertson JF; Semiglazov V; Nemsadze G; Dzagnidze G; Janjalia M; Nicholson RI; Gee JM; Armstrong J;
    Eur J Cancer; 2007 Jan; 43(1):64-70. PubMed ID: 17064888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
    Robertson JF; Nicholson RI; Bundred NJ; Anderson E; Rayter Z; Dowsett M; Fox JN; Gee JM; Webster A; Wakeling AE; Morris C; Dixon M
    Cancer Res; 2001 Sep; 61(18):6739-46. PubMed ID: 11559545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
    Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
    Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
    Xu B; Jiang Z; Shao Z; Wang J; Feng J; Song S; Chen Z; Gu K; Yu S; Zhang Y; Wang C; Zhang F; Yang J
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):223-30. PubMed ID: 20938664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
    Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
    J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience.
    Steger GG; Bartsch R; Wenzel C; Pluschnig U; Hussian D; Sevelda U; Locker GJ; Gnant MF; Jakesz R; Zielinski CC
    Eur J Cancer; 2005 Nov; 41(17):2655-61. PubMed ID: 16230005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
    Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
    Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
    Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
    Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A good drug made better: the fulvestrant dose-response story.
    Robertson JF; Lindemann J; Garnett S; Anderson E; Nicholson RI; Kuter I; Gee JM
    Clin Breast Cancer; 2014 Dec; 14(6):381-9. PubMed ID: 25457991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
    Catania C; Ascione G; Adamoli L; De Pas T; Medici M; Franceschelli L; Verri E; Magni E; Sanna G; Torrisi R; Goldhirsch A; Nolè F
    Breast Cancer Res Treat; 2007 Nov; 106(1):97-103. PubMed ID: 17260095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.
    Agrawal A; Robertson JF; Cheung KL; Gutteridge E; Ellis IO; Nicholson RI; Gee JM
    Int J Cancer; 2016 Jan; 138(1):146-59. PubMed ID: 26178788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: a Japanese study.
    Watanabe T; Sano M; Ohno S; Inaji H; Nishimura R; Shin E; Nomura Y; Morris C
    Anticancer Res; 2004; 24(2C):1275-80. PubMed ID: 15154660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
    Massarweh S; Romond E; Black EP; Van Meter E; Shelton B; Kadamyan-Melkumian V; Stevens M; Elledge R
    Breast Cancer Res Treat; 2014 Jan; 143(2):325-32. PubMed ID: 24327334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
    Oakman C; Moretti E; Santarpia L; Di Leo A
    Future Oncol; 2011 Feb; 7(2):173-86. PubMed ID: 21345137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer.
    Bartsch R; Mlineritsch B; Gnant M; Niernberger T; Pluschnig U; Greil R; Wenzel C; Sevelda P; Thaler J; Rudas M; Pober M; Zielinski CC; Steger GG;
    Breast Cancer Res Treat; 2009 May; 115(2):373-80. PubMed ID: 18661231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
    Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
    Massarweh S; Tham YL; Huang J; Sexton K; Weiss H; Tsimelzon A; Beyer A; Rimawi M; Cai WY; Hilsenbeck S; Fuqua S; Elledge R
    Breast Cancer Res Treat; 2011 Oct; 129(3):819-27. PubMed ID: 21792626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.